Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Opus Genetics, Inc.NASDAQ: IRD
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 43.5% from a year ago
Cash & equivalents stood at $59.96M at the end of Q1 FY2026, up 43.5% from a year earlier and up 33.0% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.
Context
- Cash & equivalents amounted to 89.8% of total assets at the end of Q1 FY2026, up 3.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +43.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 45.09M USD
- Year-over-year change
- +48.7%
- 4-year CAGR
- +16.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.09M | +48.7% |
| FY2024 | 2024-12-31 | 30.32M | -40.0% |
| FY2023 | 2023-12-31 | 50.5M | +18.5% |
| FY2022 | 2022-12-31 | 42.63M | +73.8% |
| FY2021 | 2021-12-31 | 24.53M | — |
Cash & Equivalents vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 cash & equivalents of $59.96M is the 2nd highest of the 10 companies compared; the peer median is $31.13M.
- Its year-over-year change of +43.5% is the 5th highest of 10, against a peer median of +1.3%.
- Cash & equivalents amounts to 89.8% of total assets for IRD, versus a peer median of 25.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76.96M | +102.7% | -24.7% | 32.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $59.96M | +43.5% | +1.9% | 89.8% |
| Mar 2026 | $51.8M | +71.7% | -25.4% | 38.8% | |
| Mar 2026 | $47.32M | -9.8% | -3.9% | 17.4% | |
| Mar 2026 | $35M | +89.3% | -74.4% | 18.8% | |
| Mar 2026 | $31.13M | +89.5% | -4.0% | 86.1% | |
| Mar 2026 | $29.83M | -49.3% | -34.5% | 25.4% | |
| Mar 2026 | $26.27M | -34.2% | -1.5% | 52.8% | |
| Mar 2026 | $6.3M | +1.3% | -36.7% | 21.2% | |
| Mar 2026 | $5.02M | -67.3% | -46.7% | 2.5% | |
| Peer median (excluding IRD) | $31.13M | +1.3% | -25.4% | 25.4% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.